cs.CLOct 26, 2026

AskGLP1: A Knowledge Graph LLM Agent for Exploring GLP-1 Experience from Online Patient Narratives

Authors: Zhaoqian Xue, Anay Somani, Siddhartha Singh, Junting Mu, Zhongyin Wang, Haozheng Liu, Ayesha Khatun, Yeaeun Kwon, 

Organizations: University of Arizona · University of California, Irvine · University of Illinois Urbana-Champaign · New York University · 

Abstract

GLP-1 medications are increasingly used for weight management, and many people share their experiences online. These narratives show why people take the drugs and what they experience, but they remain unstructured and disconnected from formal pharmacovigilance. We therefore present AskGLP1, a system that transforms online patient narratives into a knowledge graph (KG) and answers questions about medication experiences. Through an LLM-assisted pipeline grounded in the MedDRA terminology, AskGLP1 screens nearly 8.5 million Reddit posts for medication experiences and distills 163,135 of them, with 2,506 WebMD reviews, into a KG of 385,790 drug-side-effect and drug-purpose relations. We find that GLP-1 experiences are source- and drug-specific. Online narratives share the most common gastrointestinal symptoms with FAERS, but they foreground everyday burdens such as fatigue and food aversion, whereas FAERS reports more often include injection-site reactions and selected serious diagnoses such as pancreatitis. We further find that posts report less nausea and vomiting for tirzepatide than for semaglutide, more fatigue for Wegovy than Ozempic and for Zepbound than Mounjaro. Evaluations show that the agent answers with verifiable evidence and declines requests for medical advice. Our findings reveal gaps between what FAERS captures and what people report online, and they call for patient-centered approaches to pharmacovigilance. Code, prompts, and evaluation questions are available at https://github.com/ZhaoqianXue/AskGLP1.

Figures & tables

Appendix figures & tables9 assets

Supplementary material from the paper’s appendix.

Appendix

Explore similar work

Jun 24, 2026

Knowledge-augmented Agentic AI for Mental Health Medication Information Seeking

Patients increasingly seek medication information online, yet safety knowledge for psychiatric drugs is split between regulatory adverse-event records, which are authoritative but abstract, and patient narratives, which are experience-near but unvalidated. Integrating them without conflating evidence and anecdote is especially consequential in psychiatry, where poorly contextualised information can amplify fear, nocebo responses, and non-adherence. Here we develop a provenance-aware, knowledge-graph-based multi-agent framework unifying 466,525 Reddit posts, 60,782 WebMD reviews, and twenty years of U.S. FDA Adverse Event Reporting System records for nine antidepressants. A large-language-model entity-recognition pipeline benchmarked against physician annotations reached highest F1 scores of 0.969 for medications and 0.973 for conditions. The two community platforms were far more concordant with each other (overlap up to a Jaccard similarity of 0.905) than with regulatory reports, indicating that patient-generated data form a partly independent safety signal. For sertraline, many adverse events appeared in community sources hundreds of days before the corresponding FDA date. A Neo4j knowledge graph grounded in ATC-N, ICD-10, and MedDRA vocabularies preserves provenance, keeping every claim traceable and regulatory facts distinct from patient experience. These results establish source-aware integration as a route to more auditable psychiatric medication information, with usefulness and patient benefit to be tested prospectively.
Mar 12, 2026

Temporally Phenotyping GLP-1RA Case Reports with Large Language Models: A Textual Time Series Corpus and Risk Modeling

Type 2 diabetes case reports describe complex clinical courses, but their timelines are often expressed in language that is difficult to reuse in longitudinal modeling. To address this gap, we developed a textual time-series corpus of 136 PubMed Open Access single-patient case reports involving glucagon-like peptide 1 receptor agonists, with clinical events associated with their most probable reference times. We evaluated automated LLM timeline extraction against gold-standard timelines annotated by clinical domain experts, assessing how well systems recovered clinical events and their timings. The best-performing LLM produced high event coverage (GPT5; 0.871) and reliable temporal sequencing across symptoms (GPT5; 0.843), diagnoses, treatments, laboratory tests, and outcomes. As a downstream demonstration, time-to-event analyses in diabetes suggested lower risk of respiratory sequelae among GLP-1 users versus non-users (HR=0.259, p<0.05), consistent with prior reports of improved respiratory outcomes. Temporal annotations and code will be released upon acceptance.
May 31, 2026

DrugClaw and DrugAudit: A Primary-Source-Grounded Agent and Authority-Aware Benchmark for Drug-Information Question Answering

Drug-information question answering is a high-stakes setting where hallucinated facts can mislead clinical decision-making and the provenance of each cited fact matters as much as the fact itself. We present DrugClaw, a multi-agent retrieval-augmented system that queries a registry of drug and pharmacovigilance skills via a reflection-driven state-machine workflow and returns answers grounded in primary regulatory or peer-reviewed records. We also contribute DrugAudit, a 3,772-item authority-aware benchmark with an evaluation panel that scores upstream-of-gold source match, token-level semantic snippet overlap, and citation faithfulness under a dual-judge LLM-as-judge protocol with inter-judge kappa = 0.88 (almost-perfect). Across DrugAudit plus drug-related subsets of MedQA (751) and PubMedQA (512), DrugClaw is top-1 on every column of the headline table: composite Evidence Index under both judges, judge-mediated answer correctness, primary-source rate (0.918, +10.1 pp over next-best), faithfulness (0.887, +5.9 pp), MedQA (0.920), and PubMedQA (0.693).